—

Rhythm Pharmaceuticals Inc(RYTM)— 同类公司组

数据截至2026-11-18 — 评分每个交易日晚间重新计算。分组标准=首先为共同的Closelook指数成分,其次为行业。Closelook研究日记,不构成投资建议。

Rhythm Pharmaceuticals Inc的Closelook综合评分为45/100,在同类公司组内排名第7位(共7家)——组内评分最高的是Halozyme Therapeutics Inc(72/100)。

名称综合动量质量估值信号距52周高点
RYTM Rhythm Pharmaceuticals Inc4582217info2.6%
HALO Halozyme Therapeutics Inc72699449info28.5%
ONC BeOne Medicines AG66876829ok5%
REGN Regeneron Pharmaceuticals Inc65907347watch3.4%
ARGX.BR Argen-X64777526ok7.1%
RIGL Rigel Pharmaceuticals Inc64758976info19.2%
UCB.BR UCB SA64757142info5.3%

评分为Closelook全部覆盖范围内的相对读数——方法论见公司评分说明。信号灯来自每日夜间信号看板。

FAQ · from the current data · as of 2026-11-18

Quick answers

Rhythm Pharmaceuticals Inc在Closelook覆盖范围内的同类公司有哪些?

分组首先基于共同的Closelook指数成分,其次基于行业:Halozyme Therapeutics Inc (HALO)、BeOne Medicines AG (ONC)、Regeneron Pharmaceuticals Inc (REGN)、Argen-X (ARGX.BR)、Rigel Pharmaceuticals Inc (RIGL)、UCB SA (UCB.BR)。

RYTM相对同类公司的评分如何?

Rhythm Pharmaceuticals Inc的综合评分为45/100,组内排名第7位(共7家),截至2026-11-18;组内最高综合评分为Halozyme Therapeutics Inc(72/100)。Closelook评分为研究日记读数,不构成评级或投资建议。

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.